期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 36, 期 -, 页码 73-85出版社
ELSEVIER
DOI: 10.1016/j.intimp.2016.04.018
关键词
Cancer immunotherapy; B cell; T cell; Immune response; Immune tolerance; B-cell-based pharmacological strategies
资金
- Scientific Research Foundation for Colleges and Universities of Education Department of Hebei Province of China [QN20131051]
- Science and Technology Dept Intent of Hebei Province of China [12276104D-58]
- Science and Technology bureau of Handan of Hebei Province of China [1223108086-4]
Emerging evidence reveals the controversial role of B cells in antitumor immunity, but the underlying mechanisms have to be explored. Three latest articles published in the issue 521 of Nature in 2015 reconfirmed the puzzling topic and put forward some explanations of how B cells regulate antitumor T-cell responses both positively and negatively. This paper attempts to demonstrate that different B-cell subpopulations have distinct immunological properties and that they are involved in either antitumor responses or immunosuppression. Recent studies supporting the positive and negative roles of B cells in tumor development were summarized comprehensively. Several specific B-cell subpopulations, such as IgG(+), IgA(+), IL-10(+), and regulatory B cells, were described in detail. The mechanisms underlying the controversial B-cell effects were mainly attributed to different B-cell subpopulations, different B-cell-derived cytokines, direct B cell-T cell interaction, different cancer categories, and different malignant stages, and the immunological interaction between B cells and T cells is mediated by dendritic cells. Promising B-cell-based antitumor strategies were proposed and novel B-cell regulators were summarized to present interesting therapeutic targets. Future investigations are needed to make sure that B-cell-based pharmacological strategies benefit cancer immunotherapy substantially. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据